PGR and neoplasm: Most subtypes of breast cancer are driven by estrogen receptor alpha (ERα), progesterone receptor (PR), and/or human epidermal growth factor receptor (HER2) cell-surface receptors, which are targeted by standard of care therapeutic agents, inhibiting tumor growth and metastasis, and prolonging patient survival [2].